Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.040 -0.040 (-1.30%)

Streaming Delayed Price Updated: 9:37 AM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗

June 10, 2026

Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug...

Via MarketBeat

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗

June 04, 2026

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated...

Via MarketBeat

Altimmune (ALT) Q1 2026 Earnings Transcript ↗

May 13, 2026

Altimmune (ALT) Q1 2026 Earnings Transcript

Via The Motley Fool

Altimmune Q1 Earnings Call Highlights ↗

May 13, 2026

Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the...

Via MarketBeat

Topics Earnings

Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗

March 05, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

What's going on in today's pre-market session ↗

April 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Via Stocktwits

Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Altimmune (ALT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’.

Via Stocktwits

Topics ETFs Government Lawsuit

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic...

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Via Stocktwits

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

October 06, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 05, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

October 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.